https://www.prnewswi...-301179606.html
"Company Expands Leadership Team as it Advances Preclinical Studies of rGDF11 in Stroke and Other Age-Related Diseases"
This is the company with which Amy Wagers (the discoverer of GDF-11) is involved. In the press release they say:
"We are focused now on advancing our first drug, rGDF11 toward the clinic both to promote recovery after stroke and to treat obesity. The expansion of our executive team and the additions to our board of directors will help to guide Elevian as we enhance our understanding of aging and age-related diseases."
but how will they patent GDF-11? Will they simply demonstrate efficacy of GDF-11 for specific applications and then obtain a use-patent, such that they will be the only ones who can use GDF-11 for, let's say, recovery from stroke, while the molecule GDF-11 itself will be unpatentable?
The r in front of GDF-11 in the press release stands for "recombinant" which simply refers to how they manufacture it.